Dynavax Technologies (NASDAQ:DVAX) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Dynavax Technologies Corporation (NASDAQ:DVAX)’s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $11.19 and traded as high as $15.67. Dynavax Technologies shares last traded at $15.63, with a volume of 1,836,179 shares changing hands.

Analysts Set New Price Targets

A number of brokerages recently issued reports on DVAX. Wall Street Zen upgraded shares of Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 27th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. Finally, William Blair lowered Dynavax Technologies from an “outperform” rating to a “hold” rating in a report on Wednesday, December 24th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $24.33.

Dynavax Technologies Stock Up 0.3%

The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of -42.38 and a beta of 0.89. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62. The business’s 50 day moving average is $12.82 and its 200-day moving average is $11.23.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. The firm had revenue of $94.88 million during the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. Equities analysts anticipate that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, COO David F. Novack sold 114,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $15.64, for a total transaction of $1,782,960.00. Following the completion of the sale, the chief operating officer owned 63,344 shares in the company, valued at $990,700.16. This represents a 64.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.98% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Dynavax Technologies by 1.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company’s stock worth $1,126,000 after acquiring an additional 1,625 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Dynavax Technologies in the 1st quarter valued at $180,000. Caxton Associates LLP acquired a new stake in Dynavax Technologies in the 1st quarter worth $225,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Dynavax Technologies by 7.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 450,089 shares of the biopharmaceutical company’s stock worth $5,838,000 after purchasing an additional 29,764 shares during the last quarter. Finally, Strs Ohio bought a new position in shares of Dynavax Technologies during the 1st quarter worth about $250,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.